R&D News | pharmaphorum

News

Metsera has now received new takeover bids from both Pfizer and Novo Nordisk, and has plumped for a sweetened $10bn offer from the latter.

News

The ESSENCE trial of Sarepta's Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.

News

Metsera says Novo Nordisk's takeover offer is superior to one filed by Pfizer, and the latter files a new lawsuit to try to force their deal through.

News

Already approved for kidney damage in lupus, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder.

News

Thousands of people from Scotland's most deprived areas will get free weight-loss jabs in a real-world study to gauge if they can save the NHS money.

News

Pfizer has filed a lawsuit to block a rival, higher bid for obesity therapy developer Metsera from Novo Nordisk, claiming it is anti-competitive.